Holly Peay's Blog – November 2014 Archive (1)
PPMD and Santhera Pharmaceuticals Team Up on New Benefit/Risk Study Focused on Pulmonary Therapies
PPMD is proud to announce a collaboration with Santhera Pharmaceuticals on a benefit/risk study that will focus specifically on patient and caregiver preferences regarding pulmonary therapies in the disease, and will be based on data from Santhera’s successful phase III clinical trial of idebenone. One of the recommendations in our community’s…
ContinueAdded by Holly Peay on November 25, 2014 at 9:00am — No Comments
Latest Blog Posts
- PPMD’s Benefit/Risk work highlighted in groundbreaking reports
- FDA Acknowledges the Importance of Benefit-Risk Preferences: Why this Matters to Duchenne
- PPMD and Santhera Pharmaceuticals Team Up on New Benefit/Risk Study Focused on Pulmonary Therapies
- Let’s improve DuchenneConnect’s informed consent. Give your opinion by September 7th.
- PPMD Benefit/Risk Study Results Published in Clinical Therapeutics
- Simple Actions: Real data can drive change
- DuchenneConnect Receives $970,000 Award
Most Popular Blog Posts
- Promising News from Sarepta on Exon 51 Skipping Trial
- Simple Actions: Real data can drive change
- Clinical Trial Expectations
- Pushing the FDA to Accelerate Treatments
- DuchenneConnect Receives $970,000 Award
- FDA Public Workshop Report – Our Message Is Having an Impact
- FDA Acknowledges the Importance of Benefit-Risk Preferences: Why this Matters to Duchenne
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
